Aptus Pharma

Why is Aptus Pharma Ltd falling/rising?

As of 01-Sep, Aptus Pharma Ltd's stock price is at 314.30, down 0.7 (-0.22%), but has shown strong performance with a year-to-date increase of 363.57%. Despite a recent short-term decline, the stock remains above key moving averages and has seen heightened investor interest.

As of 01-Sep, Aptus Pharma Ltd's stock price is currently at 314.30, reflecting a decrease of 0.7 (-0.22%). Despite this recent decline, the stock has shown significant positive performance over various periods. For instance, over the past week, it has increased by 3.97%, and over the past month, it has risen by 11.43%. Year-to-date, the stock has impressively surged by 363.57%, contrasting sharply with the Sensex, which has fallen by 9.71% during the same period.<BR><BR>Today, the stock is just 4.07% away from its 52-week high of Rs 327.1 and has outperformed its sector by 0.38%. However, it is important to note that the stock has experienced a consecutive decline over the last two days, resulting in a total drop of 2% during this period. Despite this short-term setback, Aptus Pharma is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend.<BR><BR>Additionally, there has been a notable increase in investor participation, with delivery volume on August 31 rising by 882.76% compared to the 5-day average, suggesting strong interest in the stock. The liquidity of the stock also appears sufficient for trading, as it meets the criteria based on the average traded value.<BR><BR>In summary, while Aptus Pharma Ltd is currently experiencing a slight decline in its stock price, the overall performance metrics indicate a strong upward trend over longer periods, supported by increased investor activity and favorable trading conditions.

What does Aptus Pharma do?

Aptus Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 550 Cr. It currently has no reported net sales or profits, a P/E ratio of 117.00, and a debt-equity ratio of 0.26.

Overview: <BR>Aptus Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>No specific details regarding the incorporation year or status changes are available. Additionally, there are no sales or profit reports for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 550 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 117.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.26 <BR>Return on Equity: 19.79% <BR>Price-to-Book: 23.56<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Aptus Pharma?

Aptus Pharma's peers include Shree Ganesh Rem, Bafna Pharma, Zim Laboratories, and others. Bafna Pharma has the highest 1-year return at 198.53%, while Infinium Pharma has the lowest at 0.00%.

Peers: The peers of Aptus Pharma are Shree Ganesh Rem, Bafna Pharma., Zim Laboratories, Kilitch Drugs, Valiant Laborato, Albert David, Jenburkt Pharma, Transchem, Haleos Labs Limi, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shree Ganesh Rem, Albert David, and Jenburkt Pharma, while Average management risk is found at Zim Laboratories, Kilitch Drugs, Transchem, Haleos Labs Limi, and the rest. Below Average management risk is noted at Bafna Pharma., Valiant Laborato, and Infinium Pharma. Growth is rated as Good for Kilitch Drugs, Below Average for Shree Ganesh Rem, Bafna Pharma., Zim Laboratories, Valiant Laborato, Albert David, Jenburkt Pharma, Transchem, Haleos Labs Limi, and Infinium Pharma. <BR><BR>Return Snapshot: Bafna Pharma. has the highest 1-year return at 198.53%, while Infinium Pharma has the lowest at 0.00%. Aptus Pharma's 1-year return is not available for comparison. Additionally, Zim Laboratories and Haleos Labs Limi have negative six-month returns.

Which are the latest news on Aptus Pharma?

What is the bonus history of Aptus Pharma?

Aptus Pharma recently announced a 3:2 bonus issue, with an ex-date of May 12, 2026. Shareholders on record by this date will receive 3 additional shares for every 2 shares they currently hold.

Aptus Pharma has a recent bonus issue where they announced a 3:2 bonus. The ex-date for this bonus is set for May 12, 2026. This means that shareholders on record as of this date will receive additional shares in the ratio of 3 shares for every 2 shares they currently hold.